Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.30 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2169206 | 0.85 | LMNA (0.35) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL16167268 | 0.82 | LMNA (0.41) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL574826 | 0.82 | HDAC1 (0.37) | LMNAALDH1A1SMN1; SMN2KMT2AEHMT2 | |
| SCHEMBL1655486 | 0.79 | LMNA (0.38) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL321112 | 0.79 | LMNA (0.38) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL15698865 | 0.79 | SMN1; SMN2 (0.40) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL1389471 | 0.76 | LMNA (0.34) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL2033141 | 0.74 | ALDH1A1 (0.48) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL8196222 | 0.71 | ALDH1A1 (0.37) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL12814052 | 0.71 | SMN1; SMN2 (0.41) | LMNAALDH1A1SMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3962935-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | Immunogen, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2020223221-A1 | BIPARATOPIC FR-ALPHA ANTIBODIES AND IMMUNOCONJUGATES | IMMUNOGEN, INC. (US) | 2020-11-05 | — | — | WO | claimed |
| US-9670278-B2 | Folate receptor 1 antibodies and immunoconjugates and uses thereof | IMMUNOGEN, INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-3554544-A1 | ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF | Bluefin Biomedicine, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018112334-A1 | ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF | BLUEFIN BIOMEDICINE, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| EP-2538976-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | Immunogen, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| WO-2012138749-A1 | METHODS FOR DECREASING OCULAR TOXICITY OF ANTIBODY DRUG CONJUGATES | IMMUNOGEN, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2011106528-A1 | FOLATE RECEPTOR 1 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREOF | IMMUNOGEN, INC. (US) | 2011-09-01 | — | — | WO | disclosed |